The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes

Seok Kang Eun, Young Park So, Jin Kim Hyeong, Woo Ahn Chul, Moonsuk Nam, Soo Cha Bong, Kil Lim Sung, Rae Kim Kyung, Chul Lee Hyun

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

OBJECTIVE - The aim of this study was to examine the effects of rosiglitazone on adiponectin and plasma glucose levels in relation with common adiponectin gene (ACDC) polymorphisms. RESEARCH DESIGN AND METHODS - A total of 166 patients with type 2 diabetes were treated with rosiglitazone (4 mg/day) for 12 weeks without changing any of their previous medications. In all, single nucleotide polymorphism (SNP)45 and SNP276 of ACDC were examined. RESULTS - Regarding SNP45, there was a smaller reduction in the fasting plasma glucose (FPG) level and the HbA1c value in the carriers of the GG genotype than in the carriers of the other genotypes (P = 0.031 and 0.013, respectively). There was a smaller increase in the serum adiponectin concentration for the GG genotype than for the other genotypes (P = 0.003). Regarding SNP276, there was less reduction in the FPG level for the GG genotype than for the other genotypes (P = 0.001). In the haplotype analysis, the reductions in the FPG and HbA 1c levels were smaller for the GG homozygote haplotype than for the other haplotypes (P = 0.001 and 0.001, respectively). The increase in the plasma adiponectin concentration for the GG homozygots haplotype was smaller than that of the other haplotypes (P = 0.003). CONCLUSIONS - These data suggest that genetic variations in the adiponectin gene can affect the resiglitazone treatment response of the circulating adiponectin level and blood glucose control in type 2 diabetic patients.

Original languageEnglish
Pages (from-to)1139-1144
Number of pages6
JournalDiabetes Care
Volume28
Issue number5
DOIs
Publication statusPublished - 2005 May 1

Fingerprint

rosiglitazone
Adiponectin
Type 2 Diabetes Mellitus
Haplotypes
Genotype
Genes
Glucose
Fasting
Homozygote
Single Nucleotide Polymorphism
Blood Glucose
Research Design

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

Eun, S. K., So, Y. P., Hyeong, J. K., Chul, W. A., Nam, M., Bong, S. C., ... Hyun, C. L. (2005). The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care, 28(5), 1139-1144. https://doi.org/10.2337/diacare.28.5.1139
Eun, Seok Kang ; So, Young Park ; Hyeong, Jin Kim ; Chul, Woo Ahn ; Nam, Moonsuk ; Bong, Soo Cha ; Sung, Kil Lim ; Kyung, Rae Kim ; Hyun, Chul Lee. / The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. In: Diabetes Care. 2005 ; Vol. 28, No. 5. pp. 1139-1144.
@article{5fbfb8b748e5440a93bfe4c8ddddb2b0,
title = "The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes",
abstract = "OBJECTIVE - The aim of this study was to examine the effects of rosiglitazone on adiponectin and plasma glucose levels in relation with common adiponectin gene (ACDC) polymorphisms. RESEARCH DESIGN AND METHODS - A total of 166 patients with type 2 diabetes were treated with rosiglitazone (4 mg/day) for 12 weeks without changing any of their previous medications. In all, single nucleotide polymorphism (SNP)45 and SNP276 of ACDC were examined. RESULTS - Regarding SNP45, there was a smaller reduction in the fasting plasma glucose (FPG) level and the HbA1c value in the carriers of the GG genotype than in the carriers of the other genotypes (P = 0.031 and 0.013, respectively). There was a smaller increase in the serum adiponectin concentration for the GG genotype than for the other genotypes (P = 0.003). Regarding SNP276, there was less reduction in the FPG level for the GG genotype than for the other genotypes (P = 0.001). In the haplotype analysis, the reductions in the FPG and HbA 1c levels were smaller for the GG homozygote haplotype than for the other haplotypes (P = 0.001 and 0.001, respectively). The increase in the plasma adiponectin concentration for the GG homozygots haplotype was smaller than that of the other haplotypes (P = 0.003). CONCLUSIONS - These data suggest that genetic variations in the adiponectin gene can affect the resiglitazone treatment response of the circulating adiponectin level and blood glucose control in type 2 diabetic patients.",
author = "Eun, {Seok Kang} and So, {Young Park} and Hyeong, {Jin Kim} and Chul, {Woo Ahn} and Moonsuk Nam and Bong, {Soo Cha} and Sung, {Kil Lim} and Kyung, {Rae Kim} and Hyun, {Chul Lee}",
year = "2005",
month = "5",
day = "1",
doi = "10.2337/diacare.28.5.1139",
language = "English",
volume = "28",
pages = "1139--1144",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "5",

}

Eun, SK, So, YP, Hyeong, JK, Chul, WA, Nam, M, Bong, SC, Sung, KL, Kyung, RK & Hyun, CL 2005, 'The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes', Diabetes Care, vol. 28, no. 5, pp. 1139-1144. https://doi.org/10.2337/diacare.28.5.1139

The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. / Eun, Seok Kang; So, Young Park; Hyeong, Jin Kim; Chul, Woo Ahn; Nam, Moonsuk; Bong, Soo Cha; Sung, Kil Lim; Kyung, Rae Kim; Hyun, Chul Lee.

In: Diabetes Care, Vol. 28, No. 5, 01.05.2005, p. 1139-1144.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes

AU - Eun, Seok Kang

AU - So, Young Park

AU - Hyeong, Jin Kim

AU - Chul, Woo Ahn

AU - Nam, Moonsuk

AU - Bong, Soo Cha

AU - Sung, Kil Lim

AU - Kyung, Rae Kim

AU - Hyun, Chul Lee

PY - 2005/5/1

Y1 - 2005/5/1

N2 - OBJECTIVE - The aim of this study was to examine the effects of rosiglitazone on adiponectin and plasma glucose levels in relation with common adiponectin gene (ACDC) polymorphisms. RESEARCH DESIGN AND METHODS - A total of 166 patients with type 2 diabetes were treated with rosiglitazone (4 mg/day) for 12 weeks without changing any of their previous medications. In all, single nucleotide polymorphism (SNP)45 and SNP276 of ACDC were examined. RESULTS - Regarding SNP45, there was a smaller reduction in the fasting plasma glucose (FPG) level and the HbA1c value in the carriers of the GG genotype than in the carriers of the other genotypes (P = 0.031 and 0.013, respectively). There was a smaller increase in the serum adiponectin concentration for the GG genotype than for the other genotypes (P = 0.003). Regarding SNP276, there was less reduction in the FPG level for the GG genotype than for the other genotypes (P = 0.001). In the haplotype analysis, the reductions in the FPG and HbA 1c levels were smaller for the GG homozygote haplotype than for the other haplotypes (P = 0.001 and 0.001, respectively). The increase in the plasma adiponectin concentration for the GG homozygots haplotype was smaller than that of the other haplotypes (P = 0.003). CONCLUSIONS - These data suggest that genetic variations in the adiponectin gene can affect the resiglitazone treatment response of the circulating adiponectin level and blood glucose control in type 2 diabetic patients.

AB - OBJECTIVE - The aim of this study was to examine the effects of rosiglitazone on adiponectin and plasma glucose levels in relation with common adiponectin gene (ACDC) polymorphisms. RESEARCH DESIGN AND METHODS - A total of 166 patients with type 2 diabetes were treated with rosiglitazone (4 mg/day) for 12 weeks without changing any of their previous medications. In all, single nucleotide polymorphism (SNP)45 and SNP276 of ACDC were examined. RESULTS - Regarding SNP45, there was a smaller reduction in the fasting plasma glucose (FPG) level and the HbA1c value in the carriers of the GG genotype than in the carriers of the other genotypes (P = 0.031 and 0.013, respectively). There was a smaller increase in the serum adiponectin concentration for the GG genotype than for the other genotypes (P = 0.003). Regarding SNP276, there was less reduction in the FPG level for the GG genotype than for the other genotypes (P = 0.001). In the haplotype analysis, the reductions in the FPG and HbA 1c levels were smaller for the GG homozygote haplotype than for the other haplotypes (P = 0.001 and 0.001, respectively). The increase in the plasma adiponectin concentration for the GG homozygots haplotype was smaller than that of the other haplotypes (P = 0.003). CONCLUSIONS - These data suggest that genetic variations in the adiponectin gene can affect the resiglitazone treatment response of the circulating adiponectin level and blood glucose control in type 2 diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=18144431682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144431682&partnerID=8YFLogxK

U2 - 10.2337/diacare.28.5.1139

DO - 10.2337/diacare.28.5.1139

M3 - Article

C2 - 15855579

AN - SCOPUS:18144431682

VL - 28

SP - 1139

EP - 1144

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 5

ER -